The financials
BioCryst Pharmaceuticals, Inc. by the numbers
BioCryst Pharmaceuticals, Inc. (BCRX) reported revenue of $218M in Q2 2026 (quarter ended June 30, 2026), up 34% from the same quarter a year earlier. That came with a gross margin of 98% and net income of $78M (36% of revenue). For the full year FY2025, revenue was $875M (+94% year on year) and net income $264M. Its largest product in 2026-Q1 was ORLADEYO at $148M, 91% of the disclosed total, just ahead of Other Income From Contract With Customer at 3.1%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $218M | $163M | +34% |
| Gross profit | $214M | $161M | +34% |
| Operating income | $98M | $30M | +231% |
| Net income | $78M | $5.1M | +1442% |
| Diluted EPS | $0.30 | $0.02 | +1400% |
| Product | Revenue | Share |
|---|---|---|
| ORLADEYO | $148M | 91% |
| Other Income From Contract With Customer | $5.0M | 3.1% |
| License And Other | $5.0M | 3.1% |
| License | $3.0M | 1.8% |
| Collaborative And Other Research And Development | $2.0M | 1.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $163.4M (+22982%)
License And Other grew +187% year on yearOther Income From Contract With Customer -55% year on year
Segment Latestquarter on quarteryear on year
- ORLADEYO$148.3M$148.3MQoQ -year on year +11%-+11%
- Other Income From Contract With Customer$5.0M$5.0MQoQ -year on year -55%--55%
- License And Other$5.0M$5.0MQoQ -year on year +187%-+187%
- License$3.0M$3.0MQoQ +326%year on year -+326%-
- Collaborative And Other Research And Development$2.0M$2.0MQoQ -year on year +14%-+14%
- Peramivir--QoQ -year on year ---
Drug Manufacturers - Specialty & Generic
Ranks #2 of 28 by Smart Score